SGX Initiates Phase I Trials for SGX523
January 16 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals,
Inc. (NASDAQ:SGXP) today announced that it has opened enrollment in
two Phase I studies, with the first patient being treated on
January 14, 2008. The Phase I studies are designed to evaluate the
safety, tolerability and pharmacokinetic profile of SGX523, an
internally developed, orally-bioavailable, small molecule inhibitor
of the cMET receptor tyrosine kinase. The Phase I clinical trials
are open-label, dose escalation studies of SGX523 administered
orally to patients with advanced cancer who have either failed
standard therapy or for whom no standard therapy exists. The
studies are designed to explore two dosing regimens in parallel.
The continuous dosing trial will have continuous uninterrupted
twice daily dosing with patients being evaluated every 28 days for
continuation of treatment. The intermittent dosing schedule will
implement twice daily dosing on a 14 days on/7 days off therapy
schedule, cycling every 21 days. In both protocols, patients may
continue on therapy for up to 12 months as determined by the
patient's response and tolerance to SGX523. "SGX523 is our first
internally discovered clinical candidate. We are excited to begin
studying SGX523 in humans and to achieve the first of our 2008
clinical development goals," said Mike Grey, President and Chief
Executive Officer of SGX Pharmaceuticals. "With two separate dosing
schedules, we believe that we will be able to collect important
data that could serve as a basis for future clinical development
activities and position us to capitalize on the evolving cMET
opportunity." About SGX523 and cMET SGX523 has shown exceptional
selectivity for the cMET receptor tyrosine kinase over more than
200 protein kinases and has demonstrated both potent in vitro
blockage of the activity of this cancer target and in vivo activity
against various types of human cancer cells that depend on cMET for
their uncontrolled growth and proliferation. The cMET receptor
tyrosine kinase has been implicated in a wide range of cancers,
including both solid and blood tumors. cMET has been extensively
studied in the laboratory environment and, to a lesser extent, in
the clinic, with increasing data suggesting that uncontrolled
stimulation of cMET plays a key role in a variety of effects
associated with cancer, including cellular growth, increased cell
movement and invasion, and an increased ability of cancer cells to
metastasize. Other observations have implicated cMET in increased
angiogenesis. cMET activation has been observed in a wide range of
other cancer types including breast, colon, prostate, pancreatic
and gastric cancers. About SGX Pharmaceuticals SGX Pharmaceuticals
is a biotechnology company focused on the discovery, development
and commercialization of innovative cancer therapeutics. The SGX
oncology pipeline includes drug candidates from its FAST(TM) drug
discovery platform, such as next generation BCR-ABL inhibitors
being developed by SGX and in partnership with Novartis and cMET
tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors.
More information on the pipeline and drug discovery platform can be
found at http://www.sgxpharma.com/ and in the Company's various
filings with the Securities and Exchange Commission. Forward
Looking Statements Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements include, but are not limited to, the potential of SGX523
as a treatment for certain cancers, the potential outcome of Phase
I clinical studies of SGX523, the role of cMET in cancer,
statements regarding bringing compounds into the clinic and the
ability to discover, develop and commercialize cancer therapeutics.
These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development and
commercialization. For a discussion of these and other factors,
please refer to the risk factors described in the Company's annual
report on Form 10-K for the year ended December 31, 2006, the
Company's quarterly report on Form 10-Q for the three and nine
months ended September 30, 2007, as well as other filings with the
Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and SGX undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. DATASOURCE: SGX
Pharmaceuticals, Inc. CONTACT: Bonnie Feldman, Senior Director,
Investor Relations and Corporate Communications of SGX
Pharmaceuticals, Inc., +1-858-228-1647 Web site:
http://www.sgxpharma.com/
Copyright
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Aug 2023 to Aug 2024